Document is current
Any future updates will be listed below
-
Authors
Harding, Rachel J.
Xie, Yuanyun
Caron, Nicholas S.
Findlay-Black, Hailey
Lyu, Caroline
Potluri, Nalini
Chandrasekaran, Renu
Hayden, Michael R.
Leavitt, Blair R.
Langbehn, Douglas R.
Southwell, Amber L.
-
Funding
Funding for this research was provided by:
Hereditary Disease Foundation
Natural Sciences and Engineering Research Council of Canada (RGPIN-2024-05769)
National Institute of Neurological Disorders and Stroke (R01NS116099)
- License Information
-
More Information
Article History
Received: 9 December 2024
Accepted: 27 March 2025
First Online: 21 April 2025
Declarations
:
: Experiments were performed with the approval of the University of Central Florida Institute Animal Care and Use Committee (202400016) and Institutional Review Board (00002651).
: Not applicable.
: B.R.L. reports previous roles as a scientific consultant with Alnylam, sRNAlytics, Teva, Roche/Genentech, Takeda, Triplet, Ionis, Novartis, Spark, Sage, Sintetica, LifeEdit, Design, Remix Therapeutics, UniQure, and PTC Therapeutics. B.R.L. is a co-founder and the CEO of Incisive Genetics Inc. B.R.L. is a founding Co-Editor-in-Chief of the Journal of Huntington’s Disease. D.R.L. is a paid biostatistical consultant to the Huntington Study Group, Sage Pharmaceuticals, Prilenia, Guidepoint Consultants, and Uniqure for designing Huntington’s Disease trials. M.R.H. serves on the boards of Ionis Pharmaceuticals, AbCellera and 89Bio.
